Arbor Biotechnologies

Arbor Biotechnologies, founded in 2016, is a next-generation gene editing company with the slogan "Genetic medicines for genetic diseases." The company is focused on discovering and developing potentially curative genomic medicines and boasts the most extensive toolbox of proprietary genomic editors in the industry. Arbor Bio's unique capability to work backward from disease pathology allows it to choose the optimal editors or combination of editors for the disease in question. With headquarters in the United States, the company recently secured a significant $215.00M Series B investment on 09 November 2021. The investment was led by a group of prominent firms including Arch Venture Partners, Tao Capital Partners, Ally Bridge Group, ArrowMark Partners, Deep Track Capital, Logos Capital, TCG Crossover, Tekla Capital Management, Surveyor Capital, and Vertex Pharmaceuticals. Arbor Biotechnologies operates within the Biopharma, Biotechnology, and Life Sciences industries.